The investigation of molecular pathways demonstrates that master transcription factor nuclear factor-kappaB (NF-κB) functions as upstream mediator of GPX1 in CP resistance, so that NF-kB inhibition leads to CP sensitivity of NSCLC cells [89]. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.